Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression

Yu Wen Yeh, Tung Wei Hsu, Yen Hao Su, Chih Hsin Wang, Po Hsiang Liao, Ching Feng Chiu, Po Chen Tseng, Tim Mo Chen, Woan Ruoh Lee, Yuan Sheng Tzeng

Research output: Contribution to journalArticlepeer-review


Dacarbazine (DTIC) is the primary first-line treatment for advanced-stage metastatic melanoma; thus, DTIC resistance is poses a major challenge. Therefore, investigating the mechanism underlying DTIC resistance must be investigated. Dicer, a type III cytoplasmic endoribonuclease, plays a pivotal role in the maturation of miRNAs. Aberrant Dicer expression may contribute to tumor progression, clinical aggressiveness, and poor prognosis in various tumors. Dicer inhibition led to a reduction in DTIC sensitivity and an augmentation in stemness in melanoma cells. Clinical analyses indicated a low Dicer expression level as a predictor of poor prognosis factor. Metabolic alterations in tumor cells may interfere with drug response. Adenylosuccinate lyase (ADSL) is a crucial enzyme in the purine metabolism pathway. An imbalance in ADSL may interfere with the therapeutic efficacy of drugs. We discovered that DTIC treatment enhanced ADSL expression and that Dicer silencing significantly reduced ADSL expression in melanoma cells. Furthermore, ADSL overexpression reversed Dicer silencing induced DTIC resistance and cancer stemness. These findings indicate that Dicer-mediated ADSL regulation influences DTIC sensitivity and stemness in melanoma cells.

Original languageEnglish
Pages (from-to)12873-12889
Number of pages17
Issue number22
Publication statusPublished - 2023


  • adenylosuccinate lyase (ADSL)
  • dacarbazine (DTIC)
  • Dicer
  • melanoma

ASJC Scopus subject areas

  • Ageing
  • Cell Biology


Dive into the research topics of 'Silencing of Dicer enhances dacarbazine resistance in melanoma cells by inhibiting ADSL expression'. Together they form a unique fingerprint.

Cite this